As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Epilepsy Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 219 high prescribing neurologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Neurologists 32 30 30 32 30 33 32


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–22
Patient subpopulations forecasted
  • Treatment-responsive partial-onset seizures
  • Treatment-refractory partial-onset seizures
  • Treatment-responsive generalized seizures
  • Treatment-refractory generalized seizures
Drugs profiled
  • Aptiom/Zebinix
  • Banzel/Inovelon
  • Bucolam
  • Fycompa
  • Keppra
  • Lamictal
  • Lyrica
  • Oxtellar XR
  • Potiga/Trobalt
  • Vimpat
  • Ganaxolone
  • Rikelta
  • USL261



Key Findings

The market for epilepsy drugs is slowly emerging from the first patent cliff that eroded much of its value over 2008–09. Datamonitor Healthcare projects steady growth to a new peak in 2018, although a second wave of patent expiries, most notably for UCB’s Vimpat, will shrink the market to near its current valuation by 2022.

Fycompa will perform the best of the recently launched products. Eisai is an established company in the epilepsy market and has the geographic reach to target the US, Japan, and the five major EU markets. Unlike some of its competitors, Fycompa has both an innovative mode of action and is in further clinical development for generalized seizures.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726